ZÜRICH, Aug. 15, 2025 (GLOBE NEWSWIRE) — Die EAACI hat im Rahmen ihres Kongresses 2025 in Glasgow ihre Aufklärungskampagne zum Thema Antibiotikaallergien gestartet. Die Initiative ist der Beginn einer weltweiten Kampagne [...] Read more »
EAACI lança campanha global de conscientização sobre alergia a antibióticos no Congresso EAACI 2025 (EAACI Congress 2025)
ZURIQUE, Aug. 15, 2025 (GLOBE NEWSWIRE) — A EAACI lançou sua Campanha de Conscientização sobre Alergia a Antibióticos durante seu Congresso de 2025, realizado em Glasgow. A iniciativa dá [...] Read more »
L’EAACI lance une campagne mondiale de sensibilisation aux allergies aux antibiotiques lors du EAACI Congress 2025
ZURICH, 15 août 2025 (GLOBE NEWSWIRE) — L’EAACI a lancé sa Antibiotic Allergy Awareness Campaign (Campagne de sensibilisation aux allergies aux antibiotiques) à l’occasion de son Congrès 2025 [...] Read more »
EAACI Launches Global Antibiotic Allergy Awareness Campaign at EAACI Congress 2025
ZURICH, Aug. 15, 2025 (GLOBE NEWSWIRE) — EAACI has launched its Antibiotic Allergy Awareness Campaign during its 2025 Congress in Glasgow. The initiative begins a global effort to address mislabelling and its link to [...] Read more »
Healthcare Innovation Summit Africa Returns to Johannesburg – Registration Now Open
JOHANNESBURG, South Africa, Aug. 14, 2025 (GLOBE NEWSWIRE) — The Read more »
Healthcare Innovation Summit Africa Returns to Johannesburg – Registration Now Open
JOHANNESBURG, South Africa, Aug. 14, 2025 (GLOBE NEWSWIRE) — The Read more »
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A [...] Read more »
EAACI-Führung blickt auf rekordverdächtigen Kongress 2025 zurück: Ein entscheidender Moment für Allergologie und Immunologie
ZÜRICH, July 17, 2025 (GLOBE NEWSWIRE) — Mit über 7.600 Teilnehmern hat der EAACI–Kongress 2025 nicht nur aufgrund seiner Größe Schlagzeilen gemacht, sondern auch aufgrund der eindringlichen Botschaft [...] Read more »
Liderança da EAACI reflete sobre o Congresso Recorde de 2025: um momento crucial para as áreas de Alergia e Imunologia
ZURIQUE, July 17, 2025 (GLOBE NEWSWIRE) — Com mais de 7.600 delegados presentes, o Congresso da EAACI 2025 foi manchete não apenas por sua magnitude, mas pela mensagem poderosa transmitida por sua liderança. Agora, um [...] Read more »
La direction de l’EAACI fait le point sur son remarquable congrès 2025 représentant un tournant décisif pour l’allergologie et l’immunologie
ZURICH, 17 juill. 2025 (GLOBE NEWSWIRE) — Le congrès 2025 de l’EAACI a fait couler beaucoup d’encre à l’appui de ses 7 600 participants et plus, de son envergure et du message fort [...] Read more »
EAACI Leadership Reflects on Record-Breaking Congress 2025: A Pivotal Moment for Allergy and Immunology
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) — With over 7,600 delegates in attendance, EAACI Congress 2025 made headlines not just for its scale but for the powerful message delivered by its leadership. Now, one month [...] Read more »
Fortrea & Emery Pharma Anunciam Colaboração Estratégica para Fornecer Estudos de Interação Medicamentosa Usando Rifampicina em Conformidade com o FDA
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — A Read more »
Fortrea et Emery Pharma annoncent une collaboration stratégique visant à mener des études sur les interactions médicamenteuses répondant aux normes de la FDA en utilisant la rifampicine
DURHAM, Caroline du Nord, 24 juin 2025 (GLOBE NEWSWIRE) — Read more »
Fortrea und Emery Pharma kündigen strategische Zusammenarbeit zur Durchführung FDA-konformer Arzneimittelwechselwirkungsstudien mit Rifampin an
Durham, North Carolina, June 24, 2025 (GLOBE NEWSWIRE) — Read more »
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Read more »